These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31213500)

  • 1. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
    Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
    Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
    Chi P; Qin LX; Camacho N; Kelly CM; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Thornton KA; Crago AM; Francis JH; Martindale M; Phelan HT; Biniakewitz MD; Lee CJ; Singer S; Hwang S; Berger MF; Chen Y; Antonescu CR; Tap WD
    Clin Cancer Res; 2022 Apr; 28(8):1507-1517. PubMed ID: 35110417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
    Kelly CM; Shoushtari AN; Qin LX; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Mcfadyen C; Sjoberg A; Singer S; DeMatteo RP; Hwang S; Heinemann MH; Francis JH; Antonescu CR; Chi P; Tap WD
    Invest New Drugs; 2019 Apr; 37(2):282-290. PubMed ID: 30101387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
    Chi P; Qin LX; Nguyen B; Kelly CM; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Thornton KA; Crago AM; Yoon S; Ulaner G; Yeh R; Martindale M; Phelan HT; Biniakewitz MD; Warda S; Lee CJ; Berger MF; Schultz ND; Singer S; Hwang S; Chen Y; Antonescu CR; Tap WD
    J Clin Oncol; 2022 Mar; 40(9):997-1008. PubMed ID: 35041493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors.
    Kim HD; Ryu MH; Park YS; Yoo C; Kim SJ; Kang YK
    Clin Cancer Res; 2024 Jul; 30(13):2743-2750. PubMed ID: 38662455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
    Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
    Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
    Gelderblom H; Jones RL; George S; Valverde Morales C; Benson C; Jean-Yves Blay ; Renouf DJ; Doi T; Le Cesne A; Leahy M; Hertle S; Aimone P; Brandt U; Schӧffski P
    Br J Cancer; 2020 Apr; 122(8):1158-1165. PubMed ID: 32147671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
    Toulmonde M; Blay JY; Bouche O; Mir O; Penel N; Isambert N; Duffaud F; Bompas E; Esnaud T; Boidot R; Geneste D; Ghiringhelli F; Lucchesi C; Bellera CA; Le Loarer F; Italiano A
    Clin Cancer Res; 2019 Aug; 25(15):4611-4615. PubMed ID: 30979737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
    Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
    Joensuu H; Blay JY; Comandone A; Martin-Broto J; Fumagalli E; Grignani G; Del Muro XG; Adenis A; Valverde C; Pousa AL; Bouché O; Italiano A; Bauer S; Barone C; Weiss C; Crippa S; Camozzi M; Castellana R; Le Cesne A
    Br J Cancer; 2017 Oct; 117(9):1278-1285. PubMed ID: 28850565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
    Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
    Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.